Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Total Liabilities (2017 - 2024)

KalVista Pharmaceuticals' Total Liabilities history spans 10 years, with the latest figure at $130.5 million for Q4 2024.

  • For Q4 2024, Total Liabilities changed N/A year-over-year to $130.5 million; the TTM value through Dec 2024 reached $130.5 million, changed N/A, while the annual FY2024 figure was $28.8 million, N/A changed from the prior year.
  • Total Liabilities for Q4 2024 was $130.5 million at KalVista Pharmaceuticals, up from $26.8 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $130.5 million in Q4 2024 and bottomed at $7.6 million in Q1 2021.
  • The 4-year median for Total Liabilities is $22.6 million (2023), against an average of $27.8 million.
  • The largest annual shift saw Total Liabilities plummeted 58.97% in 2020 before it soared 30.49% in 2024.
  • A 4-year view of Total Liabilities shows it stood at $10.5 million in 2020, then fell by 27.01% to $7.6 million in 2021, then skyrocketed by 217.98% to $24.3 million in 2023, then surged by 436.93% to $130.5 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Total Liabilities are $130.5 million (Q4 2024), $26.8 million (Q4 2024), and $27.4 million (Q3 2024).